Jasper Data Show Potential Promise For Anti-CD117 Conditioning Agent

Jasper announced data on the first three patients in the trial of briquilimab in sickle cell disease and beta-thalassemia patients, not long after another player, Magenta, announced a setback in its program.

Jasper announced early data for briquilimab, its CD117-directed monoclonal antibody • Source: Shutterstock

Jasper Therapeutics, Inc. made a significant achievement with positive early data on use of briquilimab as a conditioning agent for patients with sickle cell disease (SCD) and beta-thalassemia undergoing allogeneic stem cell transplant, especially after another company seeking to develop an alternative to the chemotherapy drugs traditionally used in the space, Magenta Therapeutics, Inc., announced a setback in its own program.

Jasper said on 3 January that the first three participants in an investigator-initiated Phase I/II study of briquilimab successfully engrafted with neutrophil engraftment within 12-16 days, with the first two...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

ASCO: Rusfertide Inches Toward FDA Filing With Positive 32-Week Data

01 Jun 2025

• By Alaric DeArment

Takeda/Protagonist are awaiting 52-week data to confirm the results from the VERIFY trial of the drug in polycythemia vera.

In Brief: Bioxodes To Take Novel Hemorrhagic Stroke Drug Into Registrational Trial

24 Apr 2025

• By Sushmita Panda

The Belgium-based firm will take the first-in-class drug, based on tick saliva, targets inflammation without increasing bleeding, into a Phase IIb trial is in preparation, supported by a new series B funding round.

Sanofi Spends Big In US But Offers Crumbs Of Comfort For Europe

24 Apr 2025

• By Kevin Grogan

CFO François Roger tells Scrip the French drugmaker is flexible geographically on making investments but its spend in the US has risen regardless of the threat of tariffs.